1 unchanged sentence
Use of Proceeds from Initial Public Offering of Common Stock
−Removed: In the fourth quarter of 2021, we completed our IPO and issued and sold an aggregate of 8,119,106 shares of our common stock at a public offering price of $16.00 per share, including 766,106 shares sold pursuant to the partial exercise by the underwriters of their option to purchase additional shares.
+Added: In the fourth quarter of 2021, we completed our IPO and issued and sold an aggregate of 8,119,106 shares of our common stock, including 766,106 shares sold pursuant to the partial exercise by the underwriters of their option to purchase additional shares, at a public offering price of $16.00 per share.
The offer and sale of the shares of common stock in our IPO was registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No.
6 unchanged sentences
None of these expenses consisted of direct or indirect payments made by us to directors, officers or persons owning 10% or more of our common stock or to their associates, or to our affiliates.
−Removed: As of March 31, 2022, we estimate that we have used approximately $36.8 million of the net proceeds from our IPO.
+Added: As of June 30, 2022, we estimate that we have used approximately $54.5 million of the net proceeds from our IPO.
We maintain the unused net proceeds from the offering in cash and cash equivalents.
6 unchanged sentences
001-40925), filed with the Securities and Exchange Commission on October 26, 2021)
−Removed: Loan and Security Agreement, dated as of November 21, 2019, as amended, by and between the Registrant and Pacific Western Bank
−Removed: Service Agreement, dated June 11, 2020, as amended, by and between the Registrant and Daniel S.
−Removed: Lynch (incorporated by reference to Exhibit 10.19 to Amendment No.
−Removed: 1 to the Registrant’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission on October 18, 2021)
+Added: Amended and Restated Employment Agreement, dated June 15, 2022, by and between the Registrant and Martin Huber, M.D.
+Added: (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 16, 2022)
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10 unchanged sentences
Filed herewith.
+Added: Indicates management contract or compensatory plan or arrangement.
The certifications attached as Exhibit 32.1 is being furnished solely to accompany this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section.
2 unchanged sentences
XILIO THERAPEUTICS, INC.
+Added: August 9, 2022
/s/ René Russo
René Russo, Pharm.D.
−Removed: President, Chief Executive Officer and Director
+Added: Chief Executive Officer and Director
(Principal Executive Officer)
+Added: August 9, 2022
/s/ Salvatore Giovine
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.